Skip to main content
Premium Trial:

Request an Annual Quote

Biomax Joins Austrian Personalized Medicine Consortium

NEW YORK (GenomeWeb News) - Biomax Informatics said this week that it has been selected as a consortium partner in Austria’s OncoTyrol project Center for Personalized Cancer Medicine.
The four-year, €28 million ($43.7 million) OncoTyrol initiative focuses on “translating genomic, proteomic and metabolomic research into innovative, individualized, and cost-effective approaches for cancer diagnosis and treatment,” Biomax said.
The company will provide its BioXM knowledge-management platform for the project.
"After an in-depth evaluation we concluded that the BioXM system, with its highly visual approach and outstanding data integration capabilities, is the backbone we need” for the project, Armin Graber, head of the institute for bioinformatics at the University for Health Sciences, Medical Informatics and Technology, and head of bioinformatics and system biology for the OncoTyrol initiative, said in a statement.
OncoTyrol comprises a consortium of researchers at the Biomedical Campus Innsbruck, the University Hospital Innsbruck, and other academic and industrial partners.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.